JCR Pharmaceuticals Co., Ltd.

TSE:4552 Stock Report

Market Cap: JP¥77.5b

JCR Pharmaceuticals Past Earnings Performance

Past criteria checks 5/6

JCR Pharmaceuticals has been growing earnings at an average annual rate of 12.3%, while the Pharmaceuticals industry saw earnings growing at 5.6% annually. Revenues have been growing at an average rate of 13.1% per year. JCR Pharmaceuticals's return on equity is 9.8%, and it has net margins of 12.8%.

Key information

12.3%

Earnings growth rate

12.1%

EPS growth rate

Pharmaceuticals Industry Growth3.4%
Revenue growth rate13.1%
Return on equity9.8%
Net Margin12.8%
Next Earnings Update30 Jul 2024

Recent past performance updates

Recent updates

JCR Pharmaceuticals Co., Ltd. (TSE:4552) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

May 22
JCR Pharmaceuticals Co., Ltd. (TSE:4552) Shares May Have Slumped 28% But Getting In Cheap Is Still Unlikely

JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00

Mar 18
JCR Pharmaceuticals (TSE:4552) Is Due To Pay A Dividend Of ¥10.00

JCR Pharmaceuticals (TSE:4552) Has Affirmed Its Dividend Of ¥10.00

Feb 29
JCR Pharmaceuticals (TSE:4552) Has Affirmed Its Dividend Of ¥10.00

Revenue & Expenses Breakdown

How JCR Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TSE:4552 Revenue, expenses and earnings (JPY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 2442,8715,50712,48511,234
31 Dec 2341,3655,36414,3218,802
30 Sep 2343,0348,06313,1728,802
30 Jun 2335,5454,01411,9218,802
31 Mar 2334,3433,77211,6788,802
31 Dec 2237,5085,15413,2677,175
30 Sep 2238,2806,23513,2527,175
30 Jun 2250,87514,34313,9437,175
31 Mar 2251,08214,50713,5117,175
31 Dec 2150,93116,54914,0715,360
30 Sep 2147,51714,89912,7715,360
30 Jun 2134,7177,65710,4835,360
31 Mar 2130,0856,8928,6245,360
31 Dec 2026,1284,1377,2435,997
30 Sep 2024,4962,9836,6855,997
30 Jun 2024,8073,0767,3965,997
31 Mar 2024,7812,6787,6385,997
31 Dec 1925,7093,6538,9094,354
30 Sep 1924,1213,2609,0004,354
30 Jun 1923,6383,8027,8024,354
31 Mar 1923,1603,7157,2714,354
31 Dec 1820,8742,4547,1774,211
30 Sep 1820,6822,5666,7454,211
30 Jun 1820,8852,8576,6424,211
31 Mar 1820,5943,0706,4704,211
31 Dec 1720,2332,9306,5024,071
30 Sep 1719,7382,7226,3874,071
30 Jun 1718,6702,0796,0954,071
31 Mar 1718,0851,8635,9204,071
31 Dec 1617,4831,6686,0613,348
30 Sep 1617,1901,7515,5113,348
30 Jun 1617,0911,6205,6183,348
31 Mar 1617,4381,7895,4783,348
31 Dec 1517,5942,2995,3833,334
30 Sep 1517,4822,2815,4053,334
30 Jun 1517,1921,8615,6783,334
31 Mar 1516,8551,6825,7133,334
31 Dec 1416,3801,0666,7922,202
30 Sep 1416,5161,3196,8952,202
30 Jun 1416,1171,3166,2802,202
31 Mar 1415,7051,2966,1162,202
31 Dec 1315,6691,5176,2691,991
30 Sep 1314,8189586,1501,991

Quality Earnings: 4552 has high quality earnings.

Growing Profit Margin: 4552's current net profit margins (12.8%) are higher than last year (11%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 4552's earnings have grown by 12.3% per year over the past 5 years.

Accelerating Growth: 4552's earnings growth over the past year (46%) exceeds its 5-year average (12.3% per year).

Earnings vs Industry: 4552 earnings growth over the past year (46%) exceeded the Pharmaceuticals industry 13.3%.


Return on Equity

High ROE: 4552's Return on Equity (9.8%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.